Fundraising Fox

CatalYm

5 known investors

catalym.com ↗

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a protein it identified as a cancer therapy resistance mechanism, aiming to restore anti-tumor immune activity and improve responses to checkpoint inhibitors. The company also targets cancer-related cachexia.

BiotechHealthtech

Investors · 5

Bayern KapitalLandshut · $275K – $55M
Canaan PartnersStamford · $500K – $20M
Jeito CapitalParis
Novartis Venture FundBasel · $5M – $25M
BioGeneration VenturesreportedNaarden

In the news

CatalYm raises $150m for cancer therapy visugromab - Drug Discovery World (DDW)ddw-online.com · Jul 2024German biotech raises $150M on its way to tackle cancer therapy resistancelabiotech.eu · Jul 2024German biotech CatalYm cashes in on early-stage cancer data with $150M series Dfiercebiotech.com · Jul 2024CatalYm Raises $150M in Series D Fundingfinsmes.com · Jul 2024Catalym raises US$150m - European Biotechnology Magazineeuropean-biotechnology.com · Jul 2024CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patientsglobenewswire.com · Nov 2020

Frequently asked questions

What does CatalYm do?
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a protein it identified as a cancer therapy resistance mechanism, aiming to restore anti-tumor immune activity and improve responses to checkpoint inhibitors. The company also targets cancer-related cachexia.
Who are CatalYm's investors?
CatalYm's investors include Bayern Kapital, Canaan Partners, Jeito Capital, Novartis Venture Fund, BioGeneration Ventures.